Article
The FDA has authorized Akorn Inc. to market Paramyd, a topical mydriatic/cycloplegic combination product in eye drop form.The drops work quickly to provide short-lasting pupil dilation.
Making the grade: FDA approves first biosimilar product for retinal diseases
Advancement in TED treatment is a bright spot
Comparable conscious sedation methods address individual patient needs
Investigators uncover health care disparities among US patients
Investigators zoom in on future of dry eye treatment
Analyzing opioid prescription patterns of US retina specialists